Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Risedronate: a clinical review.

C Crandall1

  • 1Department of Medicine, University of California, Los Angeles, UCLA School of Medicine, 100 UCLA Medical Plaza, Suite 250, Los Angeles, CA 90095-7023, USA. ccrandall@mednet.ucla.edu

Archives of Internal Medicine
|February 15, 2001
PubMed
Summary

Risedronate sodium is effective for preventing and treating osteoporosis, including postmenopausal and corticosteroid-induced types. It also treats Paget disease with a good safety profile, though long-term effects are unknown.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Isolation of toxigenic Hafnia alvei from a probable case of hemolytic uremic syndrome.

Infection·2006
Same author

Cross-sectional association between markers of inflammation and serum sex steroid levels in the postmenopausal estrogen/progestin interventions trial.

Journal of women's health (2002)·2006
Same author

Antenatal psychiatric illness and adequacy of prenatal care in an ethnically diverse inner-city obstetric population.

Archives of women's mental health·2005
Same author

Bone mineral density and adjuvant therapy in breast cancer survivors.

Breast cancer research and treatment·2004
Same author

The role of serial bone mineral density testing for osteoporosis.

Journal of women's health & gender-based medicine·2001
Same author

Tolterodine: a clinical review.

Journal of women's health & gender-based medicine·2001

Area of Science:

  • Pharmacology and Therapeutics
  • Bone Metabolism and Disease
  • Clinical Trials and Evidence-Based Medicine

Background:

  • Risedronate sodium is a bisphosphonate approved for osteoporosis management.
  • Osteoporosis poses significant health risks, particularly in postmenopausal women and those on corticosteroids.

Purpose of the Study:

  • To review the efficacy and safety of risedronate sodium based on available clinical trials.
  • To assess risedronate's role in various patient populations and conditions.

Main Methods:

  • A comprehensive literature search was conducted using MEDLINE.
  • Keywords included risedronate, risedronic acid, osteoporosis, and human subjects.
  • Reference lists of retrieved articles were also reviewed.

Main Results:

  • Risedronate increases bone density in postmenopausal women and reduces fracture incidence in those with existing osteoporosis.
  • It preserves bone mass in breast cancer patients undergoing chemotherapy and prevents bone loss in corticosteroid users.
  • Risedronate is effective for Paget disease, showing improvements in pain and bone lesions, potentially outperforming etidronate.

Conclusions:

  • Risedronate sodium is a valuable treatment for postmenopausal osteoporosis, Paget disease, and corticosteroid-induced bone loss.
  • Long-term efficacy, safety data, optimal treatment duration, and comparative effectiveness against other bisphosphonates require further investigation.

Related Experiment Videos